Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1/2 × Melanoma × Toll-Like Receptor 1 × Clear all

Phase

Phase 2 3 Phase NA 1 Phase 3 1 Phase 1/2 1 Phase 1 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Interventions

pembrolizumab 66 Nivolumab 50 Ipilimumab 38 Cyclophosphamide 29 aldesleukin 23 Interleukin-2 22 Temozolomide 17 fludarabine 15 Biopsy 11 trametinib 9 fludarabine phosphate 9 dabrafenib 9 Dacarbazine 8 sargramostim 7 Paclitaxel 7 Cisplatin 7 Bevacizumab 7 lenvatinib 6 cemiplimab 6 binimetinib 6 spartalizumab 5 poly ICLC 5 montanide ISA 51 5 epacadostat 5 Vemurafenib 5 Specimen Handling 5 Radiotherapy 5 Magnetic Resonance Spectroscopy 5 Granulocyte-Macrophage Colony-Stimulating Factor 5 toripalimab 4

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03374839 2022-05-06

Nivo-TIL

Nantes University Hospital

Phase 1/2 Unknown

Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡